

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

CASWELL FILE

000508

JUL 2 1992

JUL -2 1992

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

MEMORANDUM

SUBJECT: Naphthalene: Evaluation of Mutagenicity Studies.

Barcode No.: D173073 Tox. Chem. No.: 587
Submission No.: S409546 HED Project No.: 2-0996
EPA ID No.: 055801 Case No.: 818942

FROM: Krystyna K. Locke, Toxicologist
Section I, Toxicology Branch I
Health Effects Division (H7509C)

Krystyna K. Locke 5/11/92

TO: Larry Schnaubelt/Karen Samek, PM 72
Reregistration Branch
Special Review and Reregistration Division (H7508W)

THRU: Roger Gardner, Section Head
Section I, Toxicology Branch I
Health Effects Division (H7509C)

Roger Gardner 6/16/92
15/13 6/29/92

Toxicology Branch (TB)/HED has completed an evaluation of the following mutagenicity studies with naphthalene:

- (1) Ames Salmonella/Microsome Plate Test; E.G. Godek; Pharmakon Research International, Inc.; Study No.: PH 301-TX-020-85; Study completed: September 27, 1985; Report issued: October 22, 1991.
MRID No.: 42071601
Guideline No.: 84-2a
- (2) Ames/Salmonella Plate Incorporation Assay; L.F. Stankowski; Pharmakon Research International, Inc.; Study No.: PH 301-TX-001-87; Study completed: November 15, 1987; Report issued: October 22, 1991.
MRID No.: 42071602
Guideline No.: 84-2a
- (3) Micronucleus Test (MNT) OECD; R.M. Sorg; Pharmakon Research International, Inc.; Study No.: PH 309A-TX-007-85; Study completed: October 22, 1985; Report issued: October 22, 1991.
MRID No.: 42071603
Guideline No.: 84-2b

- (4) Rat Hepatocyte Primary Culture/DNA Repair Test; T.R. Barfknecht; Pharmakon Research International, Inc.; Study No.: PH 311-TX-008-85; Study completed: September 27, 1985; Report issued: October 22, 1991.
MRID No.: 42071604
Guideline No.: 84-4

All of the studies have been classified by Tox. Branch/HED as Unacceptable. However, studies (2), (3) and (4) can be upgraded to Acceptable by submitting information on the purity of the test material (naphthalene). Study (1) cannot be upgraded because it does not satisfy the data Guideline requirement (§84-2) for genetic effects Category I, Gene Mutations. However, study (1) does not have to be repeated since another study in the same category, study (2), has been submitted by the sponsor/registrant (Texaco Chemical Company, Houston, TX). As has already been indicated, study (2) is upgradeable.

Naphthalene was not mutagenic in studies (2), (3) and (4) which are well-conducted studies. No definitive conclusions regarding the mutagenicity of naphthalene can be reached in study (1).

These studies were submitted in response to the 05/06/91 DCI for naphthalene to fulfill the 84-Mutagenicity guideline requirements.

2

DOC930057
FINAL

009563

DATA EVALUATION REPORT

Naphthalene

Study Type: Mutagenicity: Salmonella typhimurium/Mammalian Microsome
Mutagenicity Assay

Prepared for:

Health Effects Division
Office of Pesticide Programs
Environmental Protection Agency
1921 Jefferson Davis Highway
Arlington, VA 22202

Prepared by:

Clement International Corporation
9300 Lee Highway
Fairfax, VA 22031-1207

Principal Reviewer Lynne Haber Date 5/6/92
Lynne T. Haber, Ph.D.

Independent Reviewer Sharon A. Segal for Date 5/6/92
Nancy E. McGarroll, B.S.

QA/QC Manager Sharon A. Segal Date 5/6/92
Sharon Segal, Ph.D.

Contract Number: 68D10075
Work Assignment Number: 1-83
Clement Number: 91-283
Project Officer: James Scott

3

GUIDELINE SERIES 84: MUTAGENICITY
SALMONELLA

EPA Reviewer: Krystyna Locke, Toxicologist
Section I, Tox. Branch I/HED (H7509C)
EPA Section Head: Roger Gardner
Section I, Tox. Branch I/HED (H7509C)
Secondary Reviewer: Irving Mauer, Geneticist
Section I, Tox. Branch I/HED (H7509C)

Signature: Krystyna R. Locke
Date: 5/8/92
Signature: Roger Gardner
Date: 6/15/92
Signature: Irving Mauer
Date: 8-8-92

DATA EVALUATION REPORT

STUDY TYPE: Mutagenicity: Salmonella typhimurium/mammalian microsome mutagenicity assay

EPA IDENTIFICATION Numbers:

Tox. Chem. Number: 587

MRID Number: 420716-01

TEST MATERIAL: Naphthalene

SYNONYMS: None provided

SPONSOR: Texaco Chemical Company, Houston, TX

STUDY NUMBER: PH 301-TX-020-85

TESTING FACILITY: Pharmakon Research International, Inc., Waverly, PA

TITLE OF REPORT: Ames Salmonella/Microsome Plate Test

AUTHOR: Godek, E. G.

REPORT ISSUED: October 22, 1991; Study completed September 27, 1985

CONCLUSIONS--EXECUTIVE SUMMARY: No definitive conclusions can be reached from the Salmonella typhimurium/mammalian microsome plate incorporation assay conducted with naphthalene at concentrations ranging from 3 to 300 µg/plate. No evidence of mutagenicity was found at any tested concentration of naphthalene; however, there was also no cytotoxicity at the highest nonactivated or S9-activated dose in S. typhimurium strains TA1535, TA1537, TA1538, TA98, or TA100. Although the sponsor submitted a report from a repeat of this assay, in which naphthalene, tested over a comparable range (3-300 µg/plate +/-S9), was cytotoxic but not mutagenic (see Data Evaluation Record 91-284), the lack of a cytotoxic response and the absence of test material purity in the currently reviewed assay precludes the use of this study as an individual data source.

STUDY CLASSIFICATION: Unacceptable. The study does not satisfy the data Guideline requirement (§84-2) for genetic effects Category I, Gene Mutations.

SALMONELLA

However, the study does not need to be repeated since a technically acceptable S. typhimurium/mammalian microsome mutagenicity test of naphthalene, which can be upgraded by submission of test material purity information, was submitted by the sponsor.

A. MATERIALS:

1. Test Material: Naphthalene

Description: White flake
Identification number: 5601-56-1
Purity: Not reported
Receipt date: August 13, 1985
Stability: Not reported
Contaminants: None listed
Solvent used: Dimethyl sulfoxide (DMSO)
Other provided information: The test material was stored at room temperature. Dosing solutions were prepared within 4 hours of use.

2. Control Materials:

Solvent/final concentration: DMSO/100µl per plate

Positive:

Nonactivation:

Sodium azide	<u>10</u>	µg/plate	TA100, TA1535
2-Nitrofluorene	<u>5</u>	µg/plate	TA98, TA1538
9-aminoacridine	<u>150</u>	µg/plate	TA1537

Activation:

2-Anthramine	<u>2.5</u>	µg/plate	all strains
--------------	------------	----------	-------------

3. Activation: S9 derived from male Sprague-Dawley

<u>x</u>	Aroclor 1254	<u>x</u>	induced	<u>x</u>	rat	<u>x</u>	liver
_____	phenobarbital	_____	noninduced	_____	mouse	_____	lung
_____	none	_____		_____	hamster	_____	other
_____	other	_____		_____	other	_____	

The rat liver S9 homogenate was prepared by the testing laboratory on February 4, 1985 and was reported to have a protein concentration of 35.7 mg/mL.

5

SALMONELLA

S9 mix composition:

<u>Component:</u>	<u>Volume/mL</u>
Water	0.355 mL
0.2 M Phosphate buffer (pH 7.4)	0.50 mL
1 M Glucose 6-phosphate	0.005 mL
0.1 M NADP	0.04 mL
1.65 M KCl/0.4 M MgCl ₂	0.02 mL
S9	0.08 mL

4. Test Organism Used: S. typhimurium strains
 _____ TA97 x TA98 x TA100 _____ TA102 _____ TA104
 x TA1535 x TA1537 x TA1538
 list any others:

Test organisms were properly maintained: Yes.
 Checked for appropriate genetic markers (rfa mutation, R factor): Yes.

5. Test Compound Concentrations Used:

- (a) Preliminary cytotoxicity assay: Five doses (50, 166, 500, 1666, and 5000 µg/plate) were evaluated without S9 activation in S. typhimurium strains TA100 and TA1538. A single plate was used, per dose, per condition.
- (b) Mutation assay: Five doses (3, 10, 30, 100, and 300 µg/plate) were evaluated in triplicate in the presence and absence of S9 activation; all tester strains were used.

B. TEST PERFORMANCE:

1. Type of Salmonella Assay: x Standard plate test
 _____ Pre-incubation (____) minutes
 _____ "Prival" modification
 _____ Spot test
 _____ Other (describe)

2. Methods:

- (a) Preliminary cytotoxicity/mutation assays: Similar procedures were used for the preliminary cytotoxicity and the mutation assays.

Tester strains were grown to late log or early stationary phase in Oxoid broth; 0.1 mL of the appropriate tester strain and 0.1 mL of the appropriate test material dose, solvent, or positive control were added to tubes containing 2-mL volumes of molten top agar. For the S9-activated assay, 0.5 mL of the S9-cofactor mix was also added. The contents of the tubes were mixed, poured over minimal glucose plates, and incubated at 37°C for 48-72 hours. Means and

6

SALMONELLA

standard deviations for the mutation test were determined from the counts of triplicate plates per strain, per dose, per condition.

- (b) Sterility controls: The sterility of the solvent, top agar, highest test dose, and the S9 mix was determined.

3. Evaluation Criteria:

- (a) Assay validity: The assay was considered valid if the solvent control values fell within "the acceptable historical mean values." Historical means and 95% confidence limits for each strain, -/+S9 activation were: TA1535: 13.6±6.4/13.4±4.8; TA1537: 14.0±5.8/16.3±7.4; TA1538: 17.4±7.2/26.9±9.6; TA98: 29.1±8.8/40.5±15.6; and TA100: 169±71/157±69.

- (b) Positive response: The test material was considered positive if it caused a reproducible, dose-related increase in the mean number of revertants per plate of at least one strain, with at least one dose inducing a doubling of revertant levels compared to the control value. The test material was also considered positive if the maximum number of revertants induced by the test chemical was three times the solvent control.

4. Statistical Analysis: The data were analyzed for a dose response using linear regression analysis by the method of Moore and Felton¹, with a 95% confidence limit.

5. Protocol: No protocol was provided; however, a copy of the raw data was included.

C. REPORTED RESULTS

1. Preliminary Cytotoxicity Assay: Five doses of the test material ranging from 50 to 5000 µg/plate were evaluated without S9 activation using strains TA100 and TA1538. A review of the primary data accompanying the study report indicated that compound precipitation occurred at levels ≥1666 µg/plate. No revertants of either strain survived exposure to the high dose (5000 µg/plate). With strain TA1538, pinpoint colonies, indicative of a reduction in the background lawn of growth, were observed at 500 and 1666 µg/plate, and normal growth at lower doses. With strain TA100, no growth was seen at levels ≥500 µg/plate, reduced levels of revertant colonies were seen at 166 µg/plate, and normal growth was observed at 50 µg/plate. Based on these findings, the concentration range selected for the mutation assay was 3-300 µg/plate +/-S9.
2. Mutation Assay: In contrast to the results of the preliminary cytotoxicity assay, no cytotoxicity was observed with strain TA100 at

¹Moore, D. and J.S. Felton. 1983. A Microcomputer Program for Analyzing Ames Test Data. Mutat. Res. 119:95-102.

SALMONELLA

the high dose (300 µg/plate +/-S9). In addition, no cytotoxicity was seen in any other strain at any nonactivated or S9-activated dose. Similarly, there was no evidence of mutagenicity at any concentration with or without S9 activation in any of the tester strains (Table 1). All strains responded in the expected manner to the appropriate nonactivated and S9-activated positive controls. From the overall findings, the study authors concluded that naphthalene was not mutagenic in this test system.

- D. REVIEWERS' DISCUSSION/CONCLUSIONS: We assess that the study author correctly concluded that naphthalene was not mutagenic. However, the results do not fully support a negative conclusion because no cytotoxicity was demonstrated at the highest tested concentration (300 µg/mL +/-S9). Although results from the preliminary assay showed that 166 µg/plate -S9 was cytotoxic to strain TA100, no cytotoxicity was observed in this strain at 300 µg/plate +/-S9 in the mutation assay. The results from the preliminary assay showing cytotoxicity in strain TA1538 beginning at 500 µg/plate and insolubility at levels ≥1666 µg/plate should also have prompted the study author to test naphthalene at higher concentrations. In addition, there was no information on the purity of the test material.

Based on the above considerations, we conclude that the study is unacceptable. However, it is not necessary to repeat the assay, since a technically acceptable Salmonella typhimurium mutagenicity assay confirming the nonmutagenic status of naphthalene was submitted by the sponsor (see Data Evaluation Record 91-284).

- E. QUALITY ASSURANCE MEASURES: Was the test performed under GLP? Yes. (A quality assurance statement was signed and dated November 26, 1985.)
- F. CBI APPENDICES: Appendix A, Materials and Methods, CBI pp. 8-12.

CORE CLASSIFICATION: Unacceptable. As an individual data source, this study does not satisfy the data Guideline requirement (§84-2) for genetic effects Category I, Gene Mutations.

TABLE 1: Representative Results of the Salmonella typhimurium/Mammalian Microsome Mutation Assay with Naphthalene

Substance	Dose/Plate	Activation	S9					TA100
			TA1535	TA1537	TA1538	TA98	TA100	
<u>Solvent Control</u>								
Dimethyl sulfoxide	100 µL	-	17±4	12±0	19±8	31±7	172±13	
	100 µL	+	10±3	10±4	24±5	44±9	129±11	
<u>Positive Controls</u>								
Sodium azide	10 µg	-	1152±111	--	--	--	1329±18	
9-Aminoacridine	150 µg	-	--	1644±216	--	--	--	
2-Nitrofluorene	5 µg	-	--	--	565±312	579±49	--	
2-Anthramine	2.5 µg	+	217±13	259±61	1072±210	1682±221	1635±120	
<u>Test Material</u>								
Naphthalene	300 µg ^b	-	15±3	8±4	18±7	27±2	156±16	
	300 µg ^b	+	10±4	7±6	24±3	44±13	134±21	

^aMeans and standard deviations of the counts from triplicate plates.

^bResults for lower doses (3, 10, 30, and 100 µg/plate +/-S9) did not suggest a mutagenic effect.

9

Page _____ is not included in this copy.

Pages 10 through 15 are not included.

The material not included contains the following type of information:

- Identity of product inert ingredients.
 - Identity of product impurities.
 - Description of the product manufacturing process.
 - Description of quality control procedures.
 - Identity of the source of product ingredients.
 - Sales or other commercial/financial information.
 - A draft product label.
 - The product confidential statement of formula.
 - Information about a pending registration action.
 - FIFRA registration data.
 - The document is a duplicate of page(s) _____.
 - The document is not responsive to the request.
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

DOC930058
FINAL

009563

DATA EVALUATION REPORT

NAPHTHALENE

Study Type: Mutagenicity: Salmonella typhimurium/Mammalian
Microsome Mutagenicity Assay

Prepared for:

Health Effects Division
Office of Pesticide Programs
Environmental Protection Agency
1921 Jefferson Davis Highway
Arlington, VA 22202

Prepared by:

Clement International Corporation
9300 Lee Highway
Fairfax, VA 22031-1207

Principal Reviewer Sharon A. Segal for Date 5/6/92
Nancy E. McCarroll, B.S.

Independent Reviewer Lynne Haber Date 5/6/92
Lynne Haber, Ph.D.

QA/QC Manager Sharon A. Segal Date 5/6/92
Sharon Segal, Ph.D.

Contract Number: 68D10075
Work Assignment Number: 1-83
Clement Number: 91-284
Project Officer: James Scott

16

GUIDELINE § 84: MUTAGENICITY
SALMONELLA

MUTAGENICITY STUDIES

EPA Reviewer: Krystyna Locke, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)
EPA Section Head: Roger Gardner, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)
Secondary reviewer: Irving Mauer, Geneticist
Section I, Toxicology Branch I/HED (H7509C)

Signature: Krystyna R. Locke
Date: 5/8/92
Signature: Roger Gardner
Date: 6/16/92
Signature: I. Mauer
Date: 05-08-92

DATA EVALUATION REPORT

STUDY TYPE: Mutagenicity: Salmonella typhimurium mammalian microsome
mutagenicity assay

EPA IDENTIFICATION Numbers:

Tox. Chem. Number: 587

MRID Number: 420716-02

TEST MATERIAL: Naphthalene

SYNONYMS: None

SPONSOR: Texaco Chemical Co., Houston, TX

STUDY NUMBER: PH 301-TX-001-87

TESTING FACILITY: Pharmakon Research International, Inc., Waverly, PA

TITLE OF REPORT: Ames/Salmonella Plate Incorporation Assay

AUTHOR: L.F. Stankowski, Jr.

REPORT ISSUED: October 22, 1991; Study completed November 15, 1987.

CONCLUSIONS--EXECUTIVE SUMMARY: Five doses of naphthalene ranging from 3 to 300 µg/plate +/-S9 were not mutagenic in Salmonella typhimurium strains TA1535, TA1537, TA1538, TA98, or TA100. The highest dose (300 µg/plate) with and without S9 activation was cytotoxic in all strains. Based on these findings, it was concluded that naphthalene was tested over an appropriate range of concentrations with no evidence of mutagenic effect in a well-conducted study. However, the lack of purity information for the test material renders the study incomplete.

STUDY CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.2) for genetic effects Category I, Gene Mutations, but can be upgraded if test material purity information is submitted.

SALMONELLA

A. MATERIALS:

1. Test Material: Naphthalene

Description: White crystalline flakes
 Identification Number: Sample number 5601-56-1
 Purity: Not reported
 Receipt date: November 10, 1987
 Stability: Not reported
 Contaminants: None listed
 Solvent used: Dimethyl sulfoxide (DMSO)
 Other provided information: The test material was stored at room temperature. Solutions of the test material were prepared within 2 hours of use.

2. Control Materials:

Negative: None

Solvent/concentration: DMSO/100 µL/plate

Positive:

Nonactivation:

Sodium azide	<u>10</u>	µg/plate	TA1535, TA100
2-Nitrofluorene	<u>5</u>	µg/plate	TA1538, TA98
9-Aminoacridine	<u>150</u>	µg/plate	TA1537

Activation:

2.5 µg/plate all strains

3. Activation: S9 derived from male Sprague-Dawley

<u>x</u> Aroclor 1254	<u>x</u> induced	<u>x</u> rat	<u>x</u> liver
<u> </u> phenobarbital	<u> </u> noninduced	<u> </u> mouse	<u> </u> lung
<u> </u> none		<u> </u> hamster	<u> </u> other
<u> </u> other		<u> </u> other	

The rat S9 liver homogenate (lot number 4-8-87) was prepared by the performing laboratory. The S9 mix contained the following components:

<u>Component</u>	<u>Volume/mL of S9 mix</u>
0.2 M Sodium phosphate buffer (pH 7.4)	0.500 mL
1.0 M Glucose 6-phosphate	0.005 mL
0.1 M NADP	0.040 mL
0.4 M MgCl ₂ ; 1.65 M KCl	0.020 mL
Water	0.375 mL
S9	0.060 mL

4. Test Organism Used: S. typhimurium strains

<u> </u> TA97	<u>x</u> TA98	<u>x</u> TA100	<u> </u> TA102	<u> </u> TA104
<u>x</u> TA1535	<u>x</u> TA1537	<u>x</u> TA1538		

list any others:

18

SALMONELLA

Test organisms were properly maintained: Yes.
Checked for appropriate genetic markers (rfa mutation, R factor):
Yes.

5. Test Compound Concentrations Used:

- (a) Preliminary cytotoxicity assay: Five doses (50, 167, 500, 1670, and 5000 µg/plate) were evaluated without S9 activation in tester strains TA1538 and TA100. Duplicate plates were used per dose, per strain.
- (b) Mutation assay: Five doses (3, 10, 30, 100, and 300 µg/plate) were evaluated in the presence and absence of S9 activation; all tester strains were used. Triplicate plates were used per dose, per strain, per condition.

B. TEST PERFORMANCE:

1. Type of Salmonella Assay: x Standard plate test
 Pre-incubation (____) minutes
 "Prival" modification
 Spot test
 Other (describe)

(a) Preliminary cytotoxicity: The preliminary cytotoxicity was conducted with strains TA1538 and TA100 exposed to five nonactivated doses of the test material or the solvent (DMSO) control; duplicate plates were used per strain, per dose. With these exceptions, similar procedures were used for both the preliminary cytotoxicity and mutation assays.

(b) Mutation assay: To tubes containing 2-mL volumes of top agar and 0.1 mL of 10-hour broth cultures of the appropriate tester strain, 0.1 mL of the selected test material doses, or the solvent, or the positive controls were added. For the S9-activated phase of testing, 0.5 mL of the S9-cofactor mix were added. The contents of each tube were mixed and overlaid onto plates of minimal glucose medium. Plate were incubated for 48 hours at 37°C. Following incubation, the number of revertant colonies was counted, means and standard deviations were determined for the mutation assay, and the condition of the background lawn growth was determined.

The sterility of the top agar, S9 mix, solvent control, and highest test compound dose was verified.

(c) Evaluation criteria:

- (1) Assay validity: The assay was considered valid if mutant colony counts for the solvent control fell within the provided range of acceptable historical control values.

SALMONELLA

- (2) Positive response: The test material was considered positive if a dose-related increase in revertant colonies for at least one S. typhimurium strain was seen, and if at least one dose caused a 2-fold increase in the mutants over the solvent control.
2. Protocol: A protocol was not furnished; however, a copy of the primary data and historical background data was presented.

C. REPORTED RESULTS:

1. Preliminary Cytotoxicity Test: A review of the primary data indicated that the two highest doses (1670 and 5000 µg/plate) were insoluble and completely cytotoxic for both strains TA1538 and TA100. Similarly, no colonies were found on plates containing the highest soluble dose (500 µg/plate). Slight cytotoxicity, as indicated by a reduction in mutant colonies and the background lawn of growth of both tester strains, was also seen at 167 µg/plate. The lowest assayed level (50 µg/plate) was not cytotoxic. Based on this information, the nonactivated and S9-activated mutation assays were performed with a dose range of 3 to 300 µg/plate naphthalene.
2. Mutation Assays: The study author stated that all tester strains were inhibited at 300 µg/plate +/-S9. This statement was supported by comments in the primary data indicating that the background lawn of growth for all strains was reduced at this level and that the reduction was more severe without S9 activation. Mutant colony counts for all strains were also slightly lower than control at 300 µg/plate +/-S9 (Table 1). There was, however, no evidence of a mutagenic response at any nonactivated or S9-activated dose. By contrast to the negative results for naphthalene, all strains responded to the mutagenic action of the corresponding nonactivated and S9-activated positive control.

Based on the overall results, the study author concluded that naphthalene was not mutagenic in this microbial test system.

- D. REVIEWERS' DISCUSSION/CONCLUSIONS: We assess that the study author's interpretation of the data was correct. Both in the presence and the absence of S9 activation, naphthalene was tested over an appropriate range of concentrations but failed to induce a mutagenic effect. In addition, the response of all tester strains to the appropriate nonactivated and S9-activated positive control demonstrated that the assay had an adequate level of sensitivity to detect a mutagenic response. It was concluded, therefore, that naphthalene was not mutagenic in this microbial test system. However, the lack of information on test material purity renders the study incomplete.

TABLE I. Representative Results of the *Salmonella typhimurium* Mutagenicity Assay with Naphthalene

Substance	S9 Activation	Dose/plate	Revertants per Plate of Bacterial Tester Strains ^a					
			TA1535	TA1537	TA1538	TA98	TA100	
<u>Solvent Control</u>								
Dimethyl sulfoxide	-	100 µL	13±4	9±4	12±4	39±17	106±15	
	+	100 µL	17±1	11±3	32±9	43±10	114±5	
<u>Positive Controls</u>								
Sodium azide	-	10 µg	1192±55	--	--	--	1631±118	
2-Nitrofluorene	-	5 µg	--	--	897±127	561±111	--	
9-Aminoacridine	-	150 µg	--	820±163	--	--	--	
2-Aminoanthracene	+	2.5 µg	221±23	596±135	2405±234	2468±164	2756±103	
<u>Test Material</u>								
Naphthalene	-	100 µg ^b	16±3	11±5	15±2	48±4	101±18	
	-	300 µg ^c	8±0	5±1	8±0	22±7	70±14	
	+	100 µg ^b	10±3	10±3	33±7	44±5	113±10	
	+	300 µg ^c	13±5	8±6	25±1	38±5	74±8	

^aMeans and standard deviations of triplicate plates

^bResults for lower concentrations (3, 10, and 30 µg/plate +/-S9) did not suggest a mutagenic response.

^cHighest assayed dose; slight reduction in the background lawn of growth for all strains at this level.

SALMONELLA

E. QUALITY ASSURANCE MEASURES: Was test performed under GLPs? Yes. (A quality assurance statement was signed and dated November 21, 1987).

F. CBI APPENDIX: Appendix A, Materials and Methods, CBI pp. 8-11.

CORE CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.2) for genetic effects Category I, Gene Mutations, but can be upgraded pending the submission of test material purity.

Page _____ is not included in this copy.

Pages 23 through 27 are not included.

The material not included contains the following type of information:

- Identity of product inert ingredients.
 - Identity of product impurities.
 - Description of the product manufacturing process.
 - Description of quality control procedures.
 - Identity of the source of product ingredients.
 - Sales or other commercial/financial information.
 - A draft product label.
 - The product confidential statement of formula.
 - Information about a pending registration action.
 - FIFRA registration data.
 - The document is a duplicate of page(s) _____.
 - The document is not responsive to the request.
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

DOC 930059
FINAL

009568

DATA EVALUATION REPORT

NAPHTHALENE

Study Type: Mutagenicity: In Vivo Micronucleus Assay in Mice

Prepared for:

Health Effects Division
Office of Pesticide Programs
Environmental Protection Agency
1921 Jefferson Davis Highway
Arlington, VA 22202

Prepared by:

Clement International Corporation
9300 Lee Highway
Fairfax, VA 22031-1207

Principal Reviewer Sharon A. Segal for Date 5/6/92
Nancy E. McCarroll, B.S.

Independent Reviewer Lynne Haber Date 5/6/92
Lynne Haber, Ph.D.

QA/QC Manager Sharon A. Segal Date 5/6/92
Sharon Segal, Ph.D.

Contract Number: 68D10075
Work Assignment Number: 1-83
Clement Number: 91-285
Project Officer: James Scott

28

GUIDELINE § 84: MUTAGENICITY
MICRONUCLEUS

MUTAGENICITY STUDIES

EPA Reviewer: Krystyna Locke, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)

Signature: Krystyna K. Locke
Date: 5/8/92

EPA Section Head: Roger Gardner, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)

Signature: Roger Gardner
Date: 6/16/92

Secondary reviewer: Irving Mauer, Geneticist
Section I, Toxicology Branch I/HED (H7509C)

Signature: Irving Mauer
Date: 05-08-92

DATA EVALUATION REPORT

STUDY TYPE: Mutagenicity: In vivo micronucleus assay in mice

EPA IDENTIFICATION Numbers:

Tox Chem. Number: 587

MRID Number: 420716-03

TEST MATERIAL: Naphthalene

SYNONYMS: None

SPONSOR: Texaco Chemical Co., Houston, TX

STUDY NUMBER: PH 309A-TX-007-85

TESTING FACILITY: Pharmakon Research International, Inc., Waverly, PA

TITLE OF REPORT: Micronucleus Test (MNT) OECD

AUTHOR: R. M. Sorg

REPORT ISSUED: October 22, 1991; study completed October 22, 1985.

CONCLUSIONS--EXECUTIVE SUMMARY: There was no increase in the frequency of micronucleus induction in polychromatic erythrocytes harvested from the bone marrow of male and female mice 30, 48, or 72 hours postexposure to a single intraperitoneal injection of 250 mg/kg naphthalene. The evidence of overt toxicity in the treated animals (i.e., reduced body tone, abnormal gait, and lacrimation) in conjunction with cytotoxic effects on bone marrow cells (i.e., reduced polychromatic to normochromatic erythrocytes ratios at all sacrifice times) clearly indicated that the maximum tolerated dose (MTD) was achieved. We conclude, therefore, that naphthalene was assayed to an adequate dose but failed to induce a clastogenic response in a well-conducted study. However, the study is incomplete because purity information on the test material was missing.

MICRONUCLEUS

STUDY CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.2) for genetic effects Category II, Structural Aberrations. The study can, however, be upgraded if purity information on the test material is submitted.

A. MATERIALS:

1. Test Material: Naphthalene

Description: White flake

Identification Number: Sample number 5601-56-1

Purity: Not reported

Receipt date: August 13, 1985

Stability: Not reported

Contaminants: None listed

Solvent used: Corn oil

Other provided information: The test material was stored at room temperature. Solutions of the test material were prepared within 2 hours of use.

2. Control Materials:

Negative/route of administration: None

Vehicle/final concentration/route of administration: Corn oil at a dosing volume of 10 mL/kg was administered intraperitoneally (i.p.).

Positive/final concentration/route of administration: Triethylenemelamine (TEM) was dissolved in 0.9% saline and administered i.p. at 0.5 mg/kg.

3. Test Compound:

Route of administration: I.p.

Dose levels used:

- Preliminary toxicity test: 250, 500, 1666, 3000, and 5000 mg/kg
- Micronucleus assay: 250 mg/kg

4. Test Animals:

(a) Species: mouse Strain: CD-1 Age: 7 1/2-8 1/2 weeks
Weight range:

- Preliminary toxicity test: 27-33 g (males); 26-32 g (females)
- Micronucleus assay: 28-35 g (males); 26-29 g (females)

Source: Charles River Breeding Laboratories, Wilmington, MA

30

MICRONUCLEUS

(b) Number animals used per dose:

- Preliminary toxicity test: 2 males; 2 females/group
- Micronucleus assay: 5 males; 5 females/sacrifice time.

Note: Dosing was based on individual body weights determined immediately before compound administration.

(c) Properly maintained? Yes.

B. TEST PERFORMANCE:

1. Treatment and Sampling Times:

(a) Test compound:

Dosing: x once _____ twice (24 hr apart)
_____ other (describe): _____
Sampling (after last dose): _____ 6 hr _____ 12 hr
x 30 hr x 48 hr x 72 hr

(b) Vehicle control:

Dosing: x once _____ twice (24 hr apart)
_____ other (describe): _____
Sampling (after last dose): _____ 24 hr x 48 hr
_____ 72 hr

(c) Positive control:

Dosing: x once _____ twice (24 hr apart)
_____ other (describe): _____
Sampling (after last dose): x 30 hr _____ 48 hr
_____ 72 hr

2. Tissues and Cells Examined:

x bone marrow N/A others (list):
Number of polychromatic erythrocytes (PCEs) examined per
animal: 1000
Number of normochromatic erythrocytes (NCEs, more mature
RBCs) examined per animal: 1000 (PCEs+NCEs)

3. Details of Slide Preparation: At 30, 48, and 72 hours after administration of the test material, animals were sacrificed by cervical dislocation. Sacrifice times for the vehicle and positive groups were 48 and 30 hours, respectively. Bone marrow cells were flushed from both femurs, mixed with fetal bovine serum and centrifuged. Supernatants were discarded; cells were resuspended and spread onto slides. Slides were dried, fixed in absolute methanol, stained with 5% Giemsa, coverslipped, coded and scored.

4. Statistical Methods: Pairwise comparisons of the number of micronucleated PCEs (MPE) in treatment and vehicle control groups were ana-

MICRONUCLEUS

lyzed using a one-tailed t-test. The ratio of PCE:NCE for each animal was transformed using an arcsin transformation and analyzed for statistical significance by a pairwise t-test. Significance was evaluated at p values of ≤ 0.05 and ≤ 0.01 .

5. Evaluation Criteria:

- (a) Assay validity: The assay was considered valid if the percentage of MPEs in the vehicle control group was $< 0.05\%$, the positive control induced a significant effect, and at least 7 animals in the test group survived treatment.
- (b) Positive response: The test material was considered positive if it produced a significant increase in the frequency of MPEs compared to the vehicle control group.

6. Protocol: A protocol was not provided; however, a copy of the primary data was included with the study report.

C. REPORTED RESULTS:

1. Preliminary Toxicity Test: Groups of 4 mice (2 males and 2 females) received single i.p. injections of 250, 500, 1666, 3000, and 5000 mg/kg naphthalene in the preliminary toxicity test. Animals were observed for mortality and other toxic signs immediately after dosing and at 4, 24, 48, and 72 hours posttreatment. Surviving animals were sacrificed at 72 hours. Abnormal gait was observed in all animals immediately following administration of 3000 and 5000 mg/kg of the test material. By 4 hours, all animals in these groups showed signs of prostration, decreased body tone and activity, "body drop," lacrimation, and preconvulsion; 100% mortality was reported at 24 hours. Similar signs of compound toxicity preceded the death (at 24 hours) of all mice in the 500- and 1666-mg/kg groups. No deaths occurred in the low-dose group (250 mg/kg); however, clinical signs (i.e., decreased body tone, abnormal gait, and lacrimation) were also seen in this group at various times over the observation period. Based on these findings, 250 mg/kg, which the study author estimated to be the maximum tolerated dose (MTD), was selected for evaluation in the micronucleus assay.

2. Micronucleus Assay:

- (a) Animal observations: Animals were observed for death and clinical signs as described for the preliminary toxicity test. No immediate evidence of adverse effects were seen; however, 4 hours postadministration of 250 mg/kg naphthalene, 6 males and 3 females exhibited decreased body tone, and 3 males showed signs of abnormal gait. These signs were also present at 24 hours in addition to lacrimation, which was seen in ~50% of the males and ~65% of the females at this observation time. Clinical signs were essentially unchanged at 48 hours. Prior to the scheduled 72-hour sacrifice, decreased body tone and abnormal gait was

MICRONUCLEUS

reported for 4 of the remaining 10 animals (2 males and 2 females) and lacrimation for 4 animals (1 male and 3 females). These findings were consistent with the clinical signs reported for the preliminary toxicity test.

- (b) Micronucleus assay: Presented in Table 1 are the results from the micronucleus assay. As shown, PCE:NCE ratios were lower than control for males and females sacrificed at 30, 48, and 72 hours postadministration of 250 mg/kg of the test material. The effect appeared to be time related and data combined for both sexes showed a significant ($p \leq 0.05$) reduction at 72 hours. The frequency of MPEs, however, was lower in the treated males and females at all harvest times compared to the vehicle control. By contrast, significant ($p \leq 0.01$) cytotoxic and clastogenic effects were induced in males and females receiving the positive control (0.5 mg/kg TEM).

From the overall results, the study author concluded that naphthalene was negative in this in vivo test system.

- D. REVIEWERS' DISCUSSION/CONCLUSIONS: We agree with the study author's conclusion that naphthalene was negative in the mouse micronucleus assay. We further agree that the evidence of overt toxicity in the test animals and cytotoxic effects on bone marrow cells indicates that the MTD was achieved in both sexes at 250 mg/kg. In addition, the sensitivity of the test system to detect a clastogenic response was adequately demonstrated by the positive results obtained in males and females treated with 0.5 mg/kg TEM.

We concluded, however, that while naphthalene was tested to the MTD with no evidence of a positive response in the well-conducted mouse micronucleus assay, the lack of information on test material purity renders the study incomplete and, therefore, unacceptable.

- E. QUALITY ASSURANCE MEASURES: Was the test performed under GLPs? Yes. (A quality assurance statement was signed and dated October 31, 1985).

- F. CBI APPENDICES: Appendix A, Materials and Methods, CBI pp. 8-12.

CORE CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.2) for genetic effects Category II, Structural Chromosome Aberrations. The study can, however, be upgraded by submission of information on test material purity.

MICRONUCLEUS

TABLE 1. Representative Results of the Micronucleus Assay in Mice with Naphthalene

Substance	Dose/kg	Exposure Time ^a (hours)	Sex	Number of Animals Analyzed per Group	Number of FCEs ^b Analyzed per Group	Number of MPEs ^b per Group	Per 1000 PCEs	Mean FCE/NCE ^b Ratio ±S.D.
<u>Vehicle Control</u>								
Corn oil	10 mL	48	M	5	5000	7	1.4	1.256
			F	5	5000	6	1.2 (1.30±1.06) ^c	1.170 (1.21±0.43) ^c
<u>Positive Control</u>								
Triethylenemelamine	0.5 mg	30	M	5	5000	315	63.0	0.809
			F	5	5000	297	59.4 (61.20±11.09)**	0.488 (0.65±0.22)** ^d
<u>Test Material</u>								
Naphthalene	250 mg ^d	30	M	5	5000	3	0.6	1.059
			F	5	5000	3	0.6 (0.60±0.52)*	0.944 (1.00±0.17)
		48	M	5	5000	3	0.6	0.872
			F	5	5000	4	0.8 (0.70±0.82)	0.994 (0.93±0.28)
		72	M	5	5000	6	1.2	0.856
			F	5	5000	2	0.4 (0.80±63)	0.720 (0.79±0.29)*

^aTime after compound administration by intraperitoneal injection.

^bAbbreviations used:

PCE = Polychromatic erythrocytes

NCE = Normochromatic erythrocytes

MPE = Micronucleated polychromatic erythrocytes

^cValues in () are combined results for both sexes.

^dSigns of reduced body tone, abnormal gait and lacrimation were seen.

*Significantly ($p \leq 0.05$) lower than the vehicle control by pairwise t-test.

**Significantly ($p \leq 0.01$) higher than the vehicle control by pairwise t-test.

***Significantly ($p \leq 0.01$) lower than the vehicle control by pairwise t-test.

Page _____ is not included in this copy.

Pages 35 through 40 are not included.

The material not included contains the following type of information:

- Identity of product inert ingredients.
 - Identity of product impurities.
 - Description of the product manufacturing process.
 - Description of quality control procedures.
 - Identity of the source of product ingredients.
 - Sales or other commercial/financial information.
 - A draft product label.
 - The product confidential statement of formula.
 - Information about a pending registration action.
 - FIFRA registration data.
 - The document is a duplicate of page(s) _____.
 - The document is not responsive to the request.
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

000508

DOC 930060
FINAL

DATA EVALUATION REPORT

NAPHTHALENE

Study Type: Mutagenicity: Unscheduled DNA Synthesis
Assay in Primary Rat Hepatocytes

Prepared for:

Health Effects Division
Office of Pesticide Programs
Environmental Protection Agency
1921 Jefferson Davis Highway
Arlington, VA 22202

Prepared by:

Clement International Corporation
9300 Lee Highway
Fairfax, VA 22031-1207

Principal Reviewer Sharon A. Segal for Date 5/6/92
Nancy E. McCarroll, B.S.

Independent Reviewer Lynne Haber Date 5/6/92
Lynne Haber, Ph.D.

QA/QC Manager Sharon A. Segal Date 5/6/92
Sharon Segal, Ph.D.

Contract Number: 68D10075
Work Assignment Number: 1-83
Clement Number: 91-286
Project Officer: James Scott

GUIDELINE § 84: MUTAGENICITY
UDS

MUTAGENICITY STUDIES

EPA Reviewer: Krystyna Locke, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)

Signature: Krystyna R. Locke
Date: 5/8/92

EPA Section Head: Roger Gardner, Ph.D.
Section I, Toxicology Branch I/HED (H7509C)

Signature: Roger Gardner
Date: 6/6/92

Secondary reviewer: Irving Mauer, Geneticist
Section I, Toxicology Branch I/HED (H7509C)

Signature: Irving Mauer
Date: 05-08-92

DATA EVALUATION REPORT

STUDY TYPE: Mutagenicity: In vitro unscheduled DNA synthesis assay in primary rat hepatocytes

EPA IDENTIFICATION Numbers:

Tox Chem. Number: 587

MRID Number: 420716-04

TEST MATERIAL: Naphthalene

SYNONYMS: None

SPONSOR: Texaco Chemical Co., Houston, TX

STUDY NUMBER: PH 311-TX-008-85

TESTING FACILITY: Pharmakon Research International, Inc., Waverly, PA

TITLE OF REPORT: Rat Hepatocyte Primary Culture/DNA Repair Test

AUTHOR: T.R. Barfknecht

REPORT ISSUED: October 22, 1991; study completed September 27, 1985.

CONCLUSIONS--EXECUTIVE SUMMARY: Naphthalene, over a concentration range of 0.16 to 5000 µg/mL, was evaluated for the potential to induce unscheduled DNA synthesis (UDS) in primary rat hepatocytes. Doses ≥166 µg/mL were insoluble and levels ≥50 µg/mL were cytotoxic. There was, however, no evidence of a UDS response in cells treated with 0.16, 0.5, 1.6, 5, or 16 µg/mL. We conclude, therefore, that naphthalene was adequately tested and did not induce a genotoxic response in a well-conducted assay. Nevertheless, the lack of information on test material purity renders the study incomplete.

STUDY CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.4) for genetic effects Category III, Other Mutagenic Mechanisms. The study can, however, be upgraded if test material purity information is submitted.

42

A. MATERIALS:

1. Test Material: Naphthalene

Description: White crystalline flake
Identification Number: Sample number 5601-56-1
Purity: Not reported
Receipt date: August 13, 1985
Stability: Not reported
Contaminants: None listed
Solvent used: Dimethyl sulfoxide (DMSO)
Other provided information: Storage conditions were not reported, it was assumed, however, that the test material was stored at room temperature. Solutions of the test material were prepared within 4 hours of use.

2. Indicator Cells: Primary rat hepatocytes were obtained by the in situ perfusion of the liver of a male Fischer-344 rat weighing 192 g and purchased from Charles River Breeding Laboratories, Inc.3. Control Substances: The negative control was culture medium and the solvent control was DMSO at a final concentration of 1%. 2-Acetylaminofluorene (2-AAF) at a final concentration of 1×10^{-7} M was used as the positive control.4. Culture Medium: WME: Williams' Medium E; WME+: WME with 10% fetal bovine serum.5. Test Compound Concentrations Used:

(a) Preliminary cytotoxicity assay: Not performed; cytotoxicity was assessed concurrent with the UDS assay.

(b) UDS assay: Ten doses (0.16, 0.5, 1.6, 5.0, 16, 50, 166, 500, 1666, and 5000 $\mu\text{g/mL}$) were evaluated.

B. TEST PERFORMANCE:1. Cell Preparation:

(a) Perfusion technique: The liver was perfused with Hank's balanced salts containing 0.5 mM EGTA and Hepes buffer, pH 7.35, for 4 minutes and with 100 U/mL collagenase in WME for 10 minutes. The liver was excised, removed to a culture dish containing WME, trimmed of fat and excess connective tissue, and transferred to a fresh culture dish. Hepatocytes were detached in WME containing 100 U/mL collagenase by gently combing the liver with a camel hair brush.

(b) Hepatocyte Harvest/Culture Preparation. Recovered cells were added to centrifuge tubes, brought to 35-40 mL with WME, and allowed to remain quiescent for 10 minutes. Viability was

determined by trypan blue exclusion, and 1×10^5 hepatocytes were inoculated into 12-well replicate cluster dishes containing plastic coverslips and WME+. The cultures were placed in a 37°C, 5% CO₂ incubator for a 2-hour attachment period.

2. UDS Assay:

- (a) Treatment: Prior to use, cells were rinsed and refed WME containing the selected doses of the test material, the negative (culture medium), the solvent (DMSO), or the positive control (2-AAF), and 10 µC/mL [³H] thymidine. Following exposure (18-20 hours), the cultures were washed and slides were prepared.
- (b) UDS slide preparation: Cells on coverslips were treated with 1% sodium citrate for 10-15 minutes, fixed three times with glacial acetic acid:ethanol (1:3), dried and mounted.
- (c) Preparation of autoradiographs/grain development: Slides were coated with Kodak NTB-2 emulsion, dried overnight and stored at 4°C in light-proof boxes containing a desiccant for 1 week, developed in Kodak D-19, fixed, stained with Harris Alum hematoxylin, counterstained with eosin, rinsed, dried, coded and counted.
- (d) Grain counting: The nuclear grains of 60 cells (20 cells/slide) for each dose of the test material and the negative, the solvent, and the positive controls were counted microscopically. An area/grain ratio was obtained by scoring five areas on each slide containing 3-5 nuclear grains and determining an object area count with the automatic colony counter. The mean of the differences (0.5) served as the correction factor. Net nuclear grain counts were determined by subtracting the highest cytoplasmic grain count of three nuclear-sized areas adjacent to each nucleus from the nuclear grain count of each cell.

3. Evaluation Criteria:

- (a) Assay validity: For the assay to be considered valid, the following criteria must be satisfied: (1) the solvent and untreated controls should have net nuclear grain counts of ≤ 1 and fall within the 95% confidence limits of mean historical data provided by the reporting laboratory, and (2) the positive control should yield a mean net nuclear grain count that is within one standard deviation of the historical positive control mean value for 1×10^{-5} M 2-AAF (final concentration 1×10^{-7} M 2-AAF) reported by the performing laboratory as 27.3 ± 11.5 .
- (b) Positive response: The test compound was considered positive if a minimum net nuclear grain count of five grains per nuclei was consistently observed in triplicate wells; also, where possible a dose response should be observed.

4. Protocol: A protocol was not provided; however, a copy of the primary data was included with the final report.

- C. REPORTED RESULTS: Ten doses (0.16, 0.5, 1.6, 5.0, 16, 50, 166, 500, 1666, and 5000 $\mu\text{g}/\text{mL}$) were examined in a parallel cytotoxicity and UDS assay. A review of the raw data indicated that levels $\geq 166 \mu\text{g}/\text{mL}$ formed a white precipitate in the culture medium. Cytotoxicity was reported for test material concentrations $\geq 50 \mu\text{g}/\text{mL}$. Based on this information, hepatocytes treated with 0.16 to 16 $\mu\text{g}/\text{mL}$ were scored for UDS. As the representative data presented in Table 1 indicate, none of the evaluated doses caused an increase in net nuclear grain count compared to the negative or solvent control. By contrast, a marked increase in UDS was observed in cultures treated with the positive control ($1 \times 10^{-7}\text{M}$ 2-AAF).

The study author concluded from the overall findings that naphthalene was negative in the primary rat hepatocyte UDS assay.

- D. REVIEWERS' DISCUSSION/CONCLUSIONS: We assess that naphthalene was assayed over a concentration range that included soluble (0.16-50 $\mu\text{g}/\text{mL}$) and insoluble doses (166-5000 $\mu\text{g}/\text{mL}$), and that levels $\geq 50 \mu\text{g}/\text{mL}$ were cytotoxic. The lack of a genotoxic effect was, therefore, not associated with an inability of naphthalene to penetrate cellular membranes. Similarly, the sensitivity of the test system to detect a genotoxic response was adequately demonstrated by the findings with the positive control ($1 \times 10^{-7}\text{M}$ 2-AAF).

We conclude that naphthalene was assayed over an appropriate range of concentrations and failed to induce UDS in a well-conducted assay. However, the study is incomplete because information on test material purity was not provided. The study is, therefore, classified as unacceptable but can be upgraded if the missing test material information is submitted.

- E. QUALITY ASSURANCE MEASURES: Was test performed under GLPs? Yes. (A quality assurance statement was signed and dated October 2, 1985).

- F. CBI APPENDIX: Appendix A, Materials and Methods, CBI pp. 7-10.

CORE CLASSIFICATION: Unacceptable. The study does not fully satisfy Guideline requirements (§84.4) for genetic effects Category III, Other Mutagenic Mechanisms. The study can, however, be upgraded if test material purity information is submitted.

TABLE 1. Representative Results of the Unscheduled DNA Synthesis (UDS)
Rat Hepatocyte Assay with Naphthalene

Treatment	Dose	Number of Cells Scored	Mean Nuclear Grains \pm SD ^a
<u>Negative Control</u>			
Untreated Culture	--	60	0.2 \pm 0.6
<u>Solvent Control</u>			
Dimethyl sulfoxide	1%	60	0.4 \pm 1.0
<u>Positive Control</u>			
2-Acetamidofluorene	1x10 ⁻⁷ M	60	23.9 \pm 6.9 ^b
<u>Test Material</u>			
Naphthalene	16 μ g/mL ^c	60	0.0 \pm 0.1

^aMeans and standard deviations from the counts of three slides (20 cells/slide).

^bFulfills reporting laboratory's criteria for positive effect (mean net nuclear grain count of ≥ 5 over the solvent control).

^cHighest dose scored; higher levels (50, 166, 500, 1666, and 5000 μ g/mL) were cytotoxic. Results for lower concentrations (0.16, 0.5, 1.6, and 5.0 μ g/mL) were either comparable to or lower than the negative or solvent control values.

NOTE: Test material insolubility in culture medium was recorded for levels ≥ 166 μ g/mL.

Page _____ is not included in this copy.

Pages 47 through 51 are not included.

The material not included contains the following type of information:

- Identity of product inert ingredients.
 - Identity of product impurities.
 - Description of the product manufacturing process.
 - Description of quality control procedures.
 - Identity of the source of product ingredients.
 - Sales or other commercial/financial information.
 - A draft product label.
 - The product confidential statement of formula.
 - Information about a pending registration action.
 - FIFRA registration data.
 - The document is a duplicate of page(s) _____.
 - The document is not responsive to the request.
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
